RLYB vs. VHAQ, DERM, LVTX, LTRN, MNOV, LPTX, LABP, MURA, RPHM, and CKPT
Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Viveon Health Acquisition (VHAQ), Journey Medical (DERM), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), MediciNova (MNOV), Leap Therapeutics (LPTX), Landos Biopharma (LABP), Mural Oncology (MURA), Reneo Pharmaceuticals (RPHM), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical preparations" industry.
Rallybio (NASDAQ:RLYB) and Viveon Health Acquisition (NYSE:VHAQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.
90.3% of Rallybio shares are held by institutional investors. Comparatively, 22.1% of Viveon Health Acquisition shares are held by institutional investors. 7.4% of Rallybio shares are held by insiders. Comparatively, 75.3% of Viveon Health Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Rallybio currently has a consensus target price of $12.20, indicating a potential upside of 672.15%. Given Rallybio's higher possible upside, equities analysts clearly believe Rallybio is more favorable than Viveon Health Acquisition.
Viveon Health Acquisition's return on equity of 0.00% beat Rallybio's return on equity.
In the previous week, Rallybio had 2 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 2 mentions for Rallybio and 0 mentions for Viveon Health Acquisition. Rallybio's average media sentiment score of 1.88 beat Viveon Health Acquisition's score of 0.00 indicating that Rallybio is being referred to more favorably in the media.
Rallybio received 33 more outperform votes than Viveon Health Acquisition when rated by MarketBeat users.
Rallybio has a beta of -1.63, suggesting that its share price is 263% less volatile than the S&P 500. Comparatively, Viveon Health Acquisition has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.
Summary
Rallybio beats Viveon Health Acquisition on 6 of the 11 factors compared between the two stocks.
Get Rallybio News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rallybio Competitors List
Related Companies and Tools
